[Enoxacin in the treatment of bacterial prostato-cystitis].
Thirty-three patients suffering from acute, subacute or chronic prostatovesiculitis were admitted to an open, non comparative trial. Enoxacin was administered at the daily dosage of 400 mg every 12 hours for 10 days starting from the enrollment. A second cycle of treatment was performed if cure was not obtained with the first cycle. Treatment efficacy was established by assessing patient symptoms related to the infection, such as pollakiuria and dysuria, consistency and volume of prostate and spermatic vesicles (evaluated by rectal examination and transrectal ultra-sonography); bacterioscopical and bacteriological evaluations of prostate/vesicles secretion with sensitivity testing were also carried out. All observations were collected at baseline, 5 and 30 days after the end of the first cycle and 5 days after the end of the 2nd cycle of treatment. After the first cycle of treatment, cure was obtained in 22 subjects (67%) and clinical improvement in 24 (73%). All but one patients still infected at the end of the first treatment period, showed improvement (5; 45.5%) or cure (6; 54.5%). The end of the second cycle None of the 22 patients cured with one cycle of treatment relapsed within 30 days after the end of treatment, confirming they really achieved cure. Side effects were observed only in 1 case (mild vertigo); no drop outs were observed. These results suggest that enoxacin may be successfully used in the treatment of prostato-vesiculitis.
Mantovani
F
F
Mascheroni
E
E
Dal Prà
M L
ML
Montanari
E
E
Mandressi
A
A
Austoni
E
E
Pisani
E
E
D000208:Acute Disease; D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D003556:Cystitis / Q000188:drug therapy* / Q000209:etiology; D004341:Drug Evaluation; D015365:Enoxacin / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011472:Prostatitis / Q000188:drug therapy* / Q000209:etiology
D015365:Enoxacin
L'enoxacina nel trattamento delle prostatovescicoliti batteriche.